TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Immatics N.V.
Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and  IMA401 (MAGEA4/8) and Announces Next Development Steps

Immatics reported promising Phase 1a clinical trial results for two bispecific cancer therapies, IMA402 and IMA401, demonstrating favorable tolerability and deep, durable responses in heavily pre-treated patients with solid tumors across multiple cancer types.

Insights
IDXX   positive

Rose 14% after beating Wall Street estimates and raising full-year profit outlook


IMTX   positive

Achieved clinical proof-of-concept for two product candidates, showed promising anti-tumor activity with 30% confirmed objective response rate, and outlined clear development strategies for future clinical trials